Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 4Terminated 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Thoracic 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 65Sarcoma 40Neoplasm Metastasis 22Neoplasms 20Ovarian Neoplasms 17Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Recurrence 7Leiomyosarcoma 7Kidney Neoplasms 7Melanoma 6Liposarcoma 6Hemangiosarcoma 6Glioblastoma 6Fallopian Tube Neoplasms 6Thyroid Neoplasms 5Prostatic Neoplasms 5Neurofibrosarcoma 5Lung Neoplasms 5Urinary Bladder Neoplasms 4Solid Tumors 4Sarcoma, Synovial 4Pancreatic Neoplasms 4Osteosarcoma 4Histiocytoma, Malignant Fibrous 4Dermatofibrosarcoma 4Clear-cell metastatic renal cell carcinoma 4Chondrosarcoma, Extraskeletal Myxoid 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

Docetaxel 292Prednisone 240enzalutamide 193Leuprolide 185Radiotherapy 179Abiraterone Acetate 169Magnetic Resonance Spectroscopy 163bicalutamide 141Goserelin 138Androgen Antagonists 121acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108Radiosurgery 108apalutamide 92gallium 68 PSMA-11 81abiraterone 81Specimen Handling 73darolutamide 65Surveys and Questionnaires 64Gonadotropin-Releasing Hormone 63Triptorelin Pamoate 58Radiation 57Biopsy 57Brachytherapy 54cabazitaxel 52Standard of Care 51Radiotherapy, Intensity-Modulated 51Zoledronic Acid 50pembrolizumab 49luprolide acetate gel depot 49Flutamide 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Prostatic Neoplasms × pazopanib × Clear all
NCT02009449 2024-11-15

IVY

Eli Lilly and Company

Phase 1 Completed
353 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01385228 2018-06-06

Pazopanib, Docetaxel, Prednisone Prostate

Duke University

Phase 1 Completed
36 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00486642 2017-05-24

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT00454571 2016-02-10

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

NCT00945477 2013-11-18

Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade

Illinois CancerCare, P.C.

Phase 2 Terminated
11 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡